SCHEMBL365284

SCHEMBL365284

O=C(O)C(Br)c1ccccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ACP3 P15309 1/20 0.46
CES2 O00748 2/20 0.43
CES1 P23141 2/20 0.43
ALDH1A1 P00352 1/20 0.43
CXCL8 P10145 1/20 0.42
IDO1 P14902 2/20 0.40
TDO2 P48775 2/20 0.40
IDO2 Q6ZQW0 2/20 0.40
IGFBP3 P17936 1/20 0.40
CYP1A2 P05177 2/20 0.40
CASP1 P29466 1/20 0.38
CYP3A4 P08684 1/20 0.38
CTSA P10619 1/20 0.38
FABP4 P15090 1/20 0.37
FABP5 Q01469 1/20 0.37
CACNA1G O43497 1/20 0.37
CACNA2D1 P54289 1/20 0.37
CACNA1B Q00975 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5112227 1.00 MEN1 (0.46) MEN1KMT2AACP3CES2CES1
SCHEMBL8128086 1.00 MEN1 (0.46) MEN1KMT2AACP3CES2CES1
Parachlorophenol SCHEMBL9107453 0.88 MAPK1 (0.42) MEN1KMT2AACP3CES2CES1
SCHEMBL4596673 0.87 KMT2A (0.42) MEN1KMT2AACP3ALDH1A1CXCL8
SCHEMBL16161639 0.84 TSHR (0.50) MEN1KMT2AACP3ALDH1A1CXCL8
SCHEMBL9297918 0.83 ACP3 (0.42) MEN1KMT2AACP3CES2CES1
SCHEMBL9297917 0.83 ACP3 (0.42) MEN1KMT2AACP3CES2CES1
SCHEMBL8797718 0.82 MEN1 (0.46) MEN1KMT2AACP3CES2CES1
SCHEMBL15485148 0.82 KMT2A (0.43) MEN1KMT2ACES2CES1ALDH1A1
Metacresol SCHEMBL9102481 0.82 ACHE (0.47) MEN1KMT2AALDH1A1CXCL8IGFBP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108201934-B Stone grinding device for engineering and working method thereof XUZHOU INSTITUTE OF TECHNOLOGY (CN) 2019-12-10 CN claimed
WO-2012007019-A1 PROCESS FOR THE PREPARATION OF CLOPIDOGREL AND SALTS THEREOF PHARMATHEN S.A. (GR) 2012-01-19 WO claimed
EP-1907397-B1 METHOD OF PREPARING CLOPIDOGREL AND INTERMEDIATES USED THEREIN HANMI HOLDINGS CO LTD (KR) 2011-06-29 EP claimed
US-7652140-B2 Method of preparing clopidogrel and intermediates used therein HANMI PHARM. CO., LTD (KR) 2010-01-26 US claimed
EP-1907397-A4 METHOD OF PREPARING CLOPIDOGREL AND INTERMEDIATES USED THEREIN HANMI PHARM IND CO LTD (KR) 2009-05-27 EP claimed
US-20080214821-A1 Method of Preparing Clopidogrel and Intermediates Used Therein HANMI PHARM., CO., LTD. (KR) 2008-09-04 US claimed
EP-1907397-A1 METHOD OF PREPARING CLOPIDOGREL AND INTERMEDIATES USED THEREIN Hanmi Pharm. Co., Ltd. (KR) 2008-04-09 EP claimed
WO-2007126258-A1 THE METHOD OF MAKING OPTICALLY ACTIVE 2-HALO-2-(N-SUBSTITUTED PHENYL)ACETIC ACID ESTERS AND 2-HALO-2-(N-SUBSTITUTED PHENYL)ACETIC ACIDS BY ENZYMATIC METHOD ENZYTECH, LTD (KR) 2007-11-08 WO claimed
WO-2006137628-A1 METHOD OF PREPARING CLOPIDOGREL AND INTERMEDIATES USED THEREIN HANMI PHARM. CO., LTD. (KR) 2006-12-28 WO claimed
EP-0420706-B1 Process for preparing phenylacetic derivatives of thienopyridines and intermediates alpha-bromo-phenylacetic acids SANOFI SA (FR) 1995-10-11 EP claimed
US-5189170-A Process for the preparation of phenylacetic derivatives of thieno-pyridines SANOFI (FR) 1993-02-23 US claimed
CN-115160340-A Small molecule compound with ACK1 inhibitory activity and application thereof 四川大学华西医院 2022-10-11 CN disclosed
US-11202774-B2 5-substituted 2,4-thiazolidinediones (thiohydantoins), pseudothiohydantoins, and propseudothiohydantoins for use as antiviral agents JIVA PHARMA INC. (US) 2021-12-21 US disclosed
CN-111606923-B Synthesis method of racemic clopidogrel 武汉理工大学 2021-08-24 CN disclosed
CN-106928251-B Preparation method of high-purity clopidogrel 江苏天士力帝益药业有限公司 2021-05-04 CN disclosed
US-5036156-A Bromination, hydrolysis SANOFI (FR) 1991-07-30 US disclosed
US-4275065-A USEFUL FOR SKIN GRAFTS AND ORGAN TRANSPLANTS AMERICAN HOME PRODUCTS CORPORATION (US) 1981-06-23 US disclosed
EP-0021773-A1 Thiazolo (2,3-b) benzo (and azabenzo) thiazole derivatives, process for their preparation and pharmaceutical compositions containing them AMERICAN HOME PRODUCTS CORPORATION (US) 1981-01-07 EP disclosed
US-4053626-A CHOLESTEROL LEVEL-LOWERING PHENOXYACETIC ACIDS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1977-10-11 US disclosed
US-3992386-A 4(Quinolyl)phenoxy alkanoic acid derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1976-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214821-A1 Method of Preparing Clopidogrel and Intermediates Used Therein P2RY11, PTGIS, PTGIR MEN1 2819/4885KMT2A 3115/4885ACP3 2554/4885
US-11202774-B2 5-substituted 2,4-thiazolidinediones (thiohydantoins), pseudothiohydantoins, and propseudothiohydantoins for use as antiviral agents DPP4, TPMT, DPP7 MEN1 643/4885KMT2A 1919/4885ACP3 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.